Coronavirus

Baseimmune Raises $11.3M in Series A funding to Develop Better Vaccines Faster

Retrieved on: 
Monday, February 26, 2024

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240219023333/en/
    From left to right: Baseimmune co-founders Ariane C. Gomes (Chief Scientific Officer), Phillip Kemlo (Chief Technology Officer), and Joshua Blight (Chief Executive Officer).
  • Photo credit: Baseimmune
    “We’re thrilled to have the support of a top-tier investor syndicate led by MSD Global Health Innovation Fund and IQ Capital.
  • This funding will enable us to accelerate the development of our technology, scale our programs, and expedite the delivery of impactful vaccines against future pathogens,” said Joshua Blight, CEO & Co-Founder, Baseimmune.
  • By using big data and a design algorithm, Baseimmune has been able to shorten the time it takes to develop a vaccine candidate.

Hospital PMI® at 56.6%; February 2024 Hospital ISM® Report On Business®

Retrieved on: 
Thursday, March 7, 2024

The Business Activity Index expanded for the sixth consecutive month.

Key Points: 
  • The Business Activity Index expanded for the sixth consecutive month.
  • The New Orders Index remained in expansion for the sixth straight month, and the Employment Index also remained in expansion territory.
  • LeMaster continues, "Hospital Business Survey Committee respondents indicated that patient volumes were steady and consistent with seasonal patterns.
  • Prices for supplies have been in expansion (or 'increasing') territory for 51 months, pharmaceuticals for 71 months."

Datasea Expects Approximately 1,128% Revenue Growth in 2024

Retrieved on: 
Tuesday, March 5, 2024

BEIJING, March 5, 2024 /PRNewswire/ -- Datasea Inc. (NASDAQ: DTSS) ("Datasea" or the "Company"), a Nevada corporation engaged in innovative business segments for Acoustics Intelligence and 5G-AI multimodal communication technology in China and the US, issued guidance today for expecting a revenue of approximately $86.0 million for the Company's full year ended June 30, 2024.

Key Points: 
  • BEIJING, March 5, 2024 /PRNewswire/ -- Datasea Inc. (NASDAQ: DTSS) ("Datasea" or the "Company"), a Nevada corporation engaged in innovative business segments for Acoustics Intelligence and 5G-AI multimodal communication technology in China and the US, issued guidance today for expecting a revenue of approximately $86.0 million for the Company's full year ended June 30, 2024.
  • This represents approximately a 1,128% increase from revenue of $7.0 million which was reported for fiscal year ended June 30, 2023.
  • Datasea's CEO Zhixin Liu commented, "Our guidance of approximately $86.0 million in revenue is due to projected strong results from both of our business segments.
  • Our operating model encompasses distinct customer bases and sources of revenue which we believe will create long-term value for our shareholders."

Global Central Vacuum System Market Outlook Report 2023-2029: Increasing Demand From Both Home and Business Sectors, Rising Adoption of Innovative Technology

Retrieved on: 
Thursday, February 22, 2024

DUBLIN, Feb. 22, 2024 /PRNewswire/ -- The 'Global Central Vacuum System Market - Outlook & Forecast 2024-2029' report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Feb. 22, 2024 /PRNewswire/ -- The 'Global Central Vacuum System Market - Outlook & Forecast 2024-2029' report has been added to ResearchAndMarkets.com's offering.
  • The global central vacuum systems market was valued at USD 458.38 million in 2023 and is expected to grow at a CAGR of 11.33% from 2023 to 2029.
  • Some of the major players dominating the global central vacuum systems market include Trovac, DrainVac, Nuera Air, Nilfisk Group, and Busch.
  • In Europe, the demand for central vacuum systems is experiencing an increase, driven by stringent hygiene standards in the food processing industry and concerns about air quality, and dominated the global central vacuum systems market share, accounting for over 38% in 2023.

NIH grants $2.3M to evaluate the impact of ViTrack® on maternal and child health during pregnancy

Retrieved on: 
Tuesday, February 20, 2024

NEW YORK, Feb. 20, 2024 /PRNewswire/ -- Dynocardia, developer of ViTrack, the first-of-its-kind non-invasive, wearable blood pressure (BP) and heart monitor, and NYC Health + Hospitals, the nation's largest safety net health system, are partnering on a study of hypertensive diseases of pregnancy (HDP). The study will include at least 150 women who are pregnant or have recently given birth. The perinatal study addresses a long-standing unmet need for accurate and continuous BP for reliable diagnosis of HDP and for prediction and early detection of preeclampsia. The research is being funded by a $2.3M grant from the National Institute of Health's National Heart, Lung, and Blood Institute (NHLBI).

Key Points: 
  • The research is being funded by a $2.3M grant from the National Institute of Health's National Heart, Lung, and Blood Institute (NHLBI).
  • HDP, a constellation of high BP disorders that may occur during pregnancy, affects both the mother and the child and is a leading cause of pregnancy-related complications and death globally.
  • While the risks posed by HDP have doubled over the past decade in the United States, the effects on the maternal population are not evenly distributed.
  • Moreover, pregnant women are even more vulnerable to these errors due to hemodynamic and vascular changes that occur during pregnancy.

Rebamipide May Combat Low-Grade Inflammation in Post-COVID-19 Syndrome Patients

Retrieved on: 
Monday, February 19, 2024

MILWAUKEE, Feb. 19, 2024 /PRNewswire-PRWeb/ -- Rebamipide may be useful for rehabilitation of patients with SARS-CoV-2 post-COVID syndrome according to new research being presented at the 2024 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in Washington, DC, this month.

Key Points: 
  • "This study revealed higher levels of lipopolysaccharide-binding protein, and lower levels of bacterial permeability protein in patients with post COVID syndrome.
  • Rebamipide, by reducing intestinal permeability, reduces endotoxin load, lowering the level of low-grade inflammation.
  • To explore Rebamipide's usefulness for rehabilitating SARS-CoV-2 post-COVID syndrome patients, researchers examined 62 patients, aged 42-55 years with post-COVID-19 syndrome using nonsteroidal anti-inflammatory drugs for joint pain.
  • Given the effects of SARS-CoV-2 on enterocytes, the results suggest that Rebamipide may be useful for rehabilitation of patients with SARS-CoV-2 post-COVID syndrome.

EQS-News: FORVIA HELLA: Preliminary figures for 2023 and outlook for 2024 published, competitiveness program for Europe announced

Retrieved on: 
Friday, February 16, 2024

FORVIA HELLA: Preliminary figures for 2023 and outlook for 2024 published, competitiveness program for Europe announced

Key Points: 
  • FORVIA HELLA: Preliminary figures for 2023 and outlook for 2024 published, competitiveness program for Europe announced
    The issuer is solely responsible for the content of this announcement.
  • At the same time, the Company has announced a program to further increase competitiveness in Europe in light of a significantly weakening market environment.
  • Based on our preliminary business figures, we have therefore achieved all the targets we set for the fiscal year 2023."
  • The competitiveness program for Europe was announced against the background of the significant change in market conditions in Europe.

Osivax Announces Vaccination of First Participant in First-in-Human Trial Evaluating Sarbecovirus Vaccine Candidate OVX033

Retrieved on: 
Thursday, February 15, 2024

Osivax , a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses, today announced that the first participant has been vaccinated in its new Phase 1 trial ( NCT06128382 ) evaluating OVX033, a broad-spectrum sarbecovirus vaccine candidate.

Key Points: 
  • Osivax , a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses, today announced that the first participant has been vaccinated in its new Phase 1 trial ( NCT06128382 ) evaluating OVX033, a broad-spectrum sarbecovirus vaccine candidate.
  • In a rabbit toxicology study, the vaccine candidate also showed an excellent safety and tolerance profile after intramuscular administration.
  • One single dose of OVX033 vaccine or of placebo will be administered intramuscularly in 48 healthy subjects aged 18-49 years.
  • OVX033 is based on Osivax’ cutting-edge technology, OligoDOMTM, which has already established promising proof-of-concept data with OVX836, a broad-spectrum influenza A vaccine candidate currently being evaluated in several Phase 2 clinical studies.

EQS-News: TAKKT AG: Final quarter of 2023 in line with expectations - focus on gross profit margin, cost management and cash pays off

Retrieved on: 
Thursday, February 15, 2024

TAKKT AG: Final quarter of 2023 in line with expectations - focus on gross profit margin, cost management and cash pays off

Key Points: 
  • TAKKT AG: Final quarter of 2023 in line with expectations - focus on gross profit margin, cost management and cash pays off
    The issuer is solely responsible for the content of this announcement.
  • Due to the subdued demand, TAKKT intensified its measures to improve gross profit margin, cost management, and cash generation over the course of the year.
  • "Our efforts to focus on gross profit margin, cost management and cash flow are paying off.
  • "We have responded to the weak environment and are continuing to focus on consistent cost management, our gross profit margin, and cash flow.